Month: November 2014

Advertorial: “The new formula for a healthy heart” – @RevistaSemana

Advertorial (infomercial)       IMPROVE-IT: ‘Modest’ Benefit When Adding Ezetimibe to Statins in Post-ACS Patients – Medscape “The large-scale, long-delayed, and controversial study of ezetimibe in post–acute-coronary-syndrome (ACS) patients showed a “modest” benefit in reducing cardiovascular events when ezetimibe was added to simvastatin in this population.” – No further comments (no haré más comentarios al…

About the safety and effectiveness of incretins (gliptins) in type 2 diabetic patients

  1. Towards better patient care: drugs to avoid in 2014 ―Prescrire International English – Medicamentos peligrosos (By Prescrire): analysis by Plataforma NoGracias.       – Boletin Med-Informatica, Federación Médica Colombiana. PRESCRIRE Internacional Incluye Sitagliptina, Saxagliptina y Linagliptina en Lista Negativa de Medicamentos Inservibles (2014). 2. BMJ Open Data Campaign: Incretin Mimetics “Incretin therapies—glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4…

ClinicalTrials.gov: Neglected Tropical Diseases (NTDs) ―Any questions about why “neglected”?

This is not about how many unpublished and withheld clinical trials… Re: US incentive scheme for neglected diseases: a good idea gone wrong? BMJ (August 3 2014). http://www.bmj.com/content/349/bmj.g4665/rr/762076 Featured Image: Jim Gathany – Centers for Disease Control and Prevention‘s Public Health Image Library (PHIL), ID #5814. View description on Wikimedia

About Hepatitis C therapies: sofosbuvir and ledipasvir

¿Es justo excluir a millones de personas de un medicamento que puede salvarles la vida?A propósito de la hepatitis C. Autor: nmurcia, publicado por NoGracias, Noviembre 26, 2014. Is it fair to exclude millions of people from a medication that can save their lives? About Hepatitis C. Author: nmurcia, published by NoGracias, November 26, 2014.  “Investigadores de la Universidad de Liverpool…

#AllTrials: “Patients’ and doctors’ campaign welcomes plans to tackle unjust and dangerous problem of hidden clinical trials”

Article originally posted on the AllTrials website on November 20th, 2014 (no changes were made). Read this article via AllTrials.net: http://www.alltrials.net/news/patients-and-doctors-campaign-welcomes-plans-to-tackle-unjust-and-dangerous-problem-of-hidden-clinical-trials/ The AllTrials campaign, which has been calling for all clinical trials past and present to be registered, and full methods and results made available, today welcomed new proposals by the US Department of Health and Human Services (HHS) and…

Medical Groups Shy About Detailing Industry Financial Support by Tracy Weber and Charles Ornstein ProPublica, May 5, 2011, 7:36 p.m. Republished article complying with ProPublica rules: “Steal Our Stories”. When it comes to the money they get from drug and device makers, many medical associations and health advocacy groups would rather not publicize who gave and how…

Re: Global rules for global health: why we need an independent, impartial WHO

Response to (June 19, 2014):  Sridhar Devi, Frenk J, Gostin L, Moon S. Global rules for global health: why we need an independent, impartial WHO BMJ 2014; 348:g3841. Dear Editor, I read with interest the analysis published today by Sridhar and colleagues. I would like to make the following comments: – Over 50% of strong…

Is data obtained from clinical studies in Colombia sufficiently shared?

According to ClinicalTrials.gov there are 712 studies registered for Colombia as a location for patient recruitment (Data search: December 5 2013). Most of these trials were designed to evaluate the safety and effectiveness of approved drugs in off-label conditions in postmarketing studies (phase IV) and to test investigational new drugs (clinical trials, phases one to…